Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00

Hims & Hers Health (NYSE:HIMS) had its price objective raised by Truist Financial from $27.00 to $32.00 in a research report report published on Monday, Marketbeat.com reports. The brokerage currently has a hold rating on the stock.

HIMS has been the topic of several other research reports. Morgan Stanley boosted their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. reduced their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $32.50.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $29.87 on Monday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company has a market capitalization of $6.97 billion, a PE ratio of -47.41 and a beta of 2.40. Hims & Hers Health has a one year low of $13.74 and a one year high of $65.30. The business has a 50 day simple moving average of $32.35 and a 200 day simple moving average of $26.27.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the company earned $0.17 earnings per share. The business’s revenue was up 38.2% on a year-over-year basis.

Insider Buying and Selling

In related news, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Soleil Boughton sold 25,111 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the transaction, the insider owned 313,964 shares in the company, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 186,769 shares of company stock valued at $6,035,648 in the last 90 days. 11.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. California State Teachers Retirement System raised its holdings in Hims & Hers Health by 3,404.9% during the 2nd quarter. California State Teachers Retirement System now owns 8,000,068 shares of the company’s stock worth $277,362,000 after purchasing an additional 7,771,816 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Norges Bank bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $62,153,000. Invesco Ltd. grew its position in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after buying an additional 1,600,004 shares during the period. Finally, Marex Group plc grew its position in shares of Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after buying an additional 1,496,707 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Truist reportedly issued a bullish forecast for Hims & Hers’ weight-loss revenue, supporting the view that demand for GLP-1-related treatments could remain a meaningful growth driver. Truist weight-loss revenue forecast
• Positive Sentiment: An analyst cited in coverage said GLP-1 users appear to be remaining with the platform, which may help ease concerns that customer retention or demand could weaken as the market develops. GLP-1 sales outlook
• Neutral Sentiment: The National Advertising Division reached a split decision in an advertising dispute involving Hims & Hers and Kenvue, creating a compliance and marketing-related development without a clear immediate financial impact. NAD advertising dispute
• Negative Sentiment: The Federal Trade Commission and two states are targeting alleged subscription, billing and health-data practices, including potentially deceptive cancellation procedures and improper sharing of private user information. These allegations raise possible legal costs, reputational damage and operational restrictions. FTC and state actions
• Negative Sentiment: Several shareholder law firms—including Hagens Berman, Kaplan Fox, Berger Montague, Portnoy Law, Howard G. Smith, and Glancy Prongay Wolke & Rotter—have announced investigations into potential securities-law violations, fiduciary-duty breaches and investor losses. The growing number of investigations intensifies uncertainty, although no wrongdoing has been established. Hagens Berman investigation
• Negative Sentiment: A separate report linked a recent gap lower to an analyst downgrade, while coverage also highlighted payment disputes flagged by Visa. Both developments add to concerns about customer billing quality and near-term investor confidence. Analyst downgrade

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.